Nurix Therapeutics (NRIX) EBITDA Margin Growth (1y) (2020 - 2026)
Powered by 
Analysis
Nurix Therapeutics (NRIX) EBITDA Margin Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -1,651.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,091.00 |
| 10 | Nurix Therapeutics | 2.90 Bn | 2.46 Bn | - | -93,205.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -93,205.00 |
| Feb 28, 2026 | -113,878.00 |
| Nov 30, 2025 | -12,530.00 |
| Aug 31, 2025 | -72,382.00 |
| May 31, 2025 | 29,174.00 |
| Feb 28, 2025 | -6,802.00 |
| Nov 30, 2024 | -18,767.00 |
| Aug 31, 2024 | -21,717.00 |
| May 31, 2024 | -31,417.00 |
| Feb 29, 2024 | 6,595.00 |
| Nov 30, 2023 | 41,877.00 |
| Aug 31, 2023 | 21,627.00 |
| May 31, 2023 | 31,264.00 |
| Feb 28, 2023 | 10,567.00 |
| Nov 30, 2022 | -20,467.00 |
| Aug 31, 2022 | -15,009.00 |
| May 31, 2022 | -2,739.00 |
| Feb 28, 2022 | 4,509.00 |
| Nov 30, 2021 | -21,404.00 |
| Aug 31, 2021 | 18,697.00 |